Model‐informed characterisation of the target therapeutic window for dexamethasone by quantitatively balancing foetal lung maturation and neurotoxicity in pregnant rats

Background and Purpose Dexamethasone, a first‐line treatment for neonatal respiratory distress syndrome (NRDS), promotes foetal lung maturation whilst simultaneously inducing neurotoxicity in offspring. We aimed to define the therapeutic window of dexamethasone for the treatment of NRDS. Experimental Approach Pregnant rats were given dexamethasone at 0.1 or 0.4 mg·kg −1 to simulate clinically equivalent prenatal dexamethasone exposure. Half of the rats were anaesthetised, and surfactant proteins A and B in foetal lungs quantified. A pharmacokinetic/pharmacodynamics (PK/PD) model was developed to determine the minimum effective concentration. The remaining rats, delivered naturally, and their offspring underwent open‐field testing. Messenger RNA sequencing of the foetal hippocampus was performed, and concentration‐toxicity assays were conducted using H19‐7/IGF‐IR cells. Data were integrated with a maternal‐foetal physiologically based pharmacokinetic (PBPK) model to determine the maximum tolerated concentration. A clinical PBPK for dexamethasone in pregnant women was used to simulate a potentially optimal dosing regimen. Key Results The PK/PD model adequately characterised dexamethasone‐induced foetal lung maturation and indicated a minimal effective concentration of 1.63 ng·ml −1 . The offspring of PDE rats exhibited significant behavioural changes. mRNA sequencing analysis suggested that neurotoxicity was mediated via the Wnt pathway and renin‐angiotensin system, with BDNF and CMA1 identified as potential biomarkers of neurotoxicity. Cell‐based assays suggested a neurotoxic threshold concentration of 17 ng·ml −1 . For a therapeutic window of 1.63–17 ng·ml −1 , PBPK model simulations indicated that a reduced dose regimen of 2.5 or 3 mg every 8 h for six doses may represent an optimised therapeutic strategy. Conclusion and Implications This model‐informed precision dosing strategy provides a rational approach to optimising clinical dexamethasone dosing regimens.

Authors

Institutions

Publication Details

Journal
British Journal of Pharmacology
Published
2026-11-17
DOI
https://doi.org/10.1111/bph.70737
Primary Topic
Neonatal Respiratory Health Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Model‐informed characterisation of the target therapeutic window for dexamethasone by quantitatively balancing foetal lung maturation and neurotoxicity in pregnant rats

Ruihu Du, Q L Wang, Dan Xu, Mengxi Lu et al.
British Journal of Pharmacology
Neonatal Respiratory Health Research
article

Model‐informed characterisation of the target therapeutic window for dexamethasone by quantitatively balancing foetal lung maturation and neurotoxicity in pregnant rats

Ruihu Du, Q L Wang, Dan Xu, Mengxi Lu, L. P. Zhang, Song Li, Ling Song, Xiaoqi Zhao, Jie Song, Dongyang Liu, Hui Wang
article en

Abstract

Background and Purpose Dexamethasone, a first‐line treatment for neonatal respiratory distress syndrome (NRDS), promotes foetal lung maturation whilst simultaneously inducing neurotoxicity in offspring. We aimed to define the therapeutic window of dexamethasone for the treatment of NRDS. Experimental Approach Pregnant rats were given dexamethasone at 0.1 or 0.4 mg·kg −1 to simulate clinically equivalent prenatal dexamethasone exposure. Half of the rats were anaesthetised, and surfactant proteins A and B in foetal lungs quantified. A pharmacokinetic/pharmacodynamics (PK/PD) model was developed to determine the minimum effective concentration. The remaining rats, delivered naturally, and their offspring underwent open‐field testing. Messenger RNA sequencing of the foetal hippocampus was performed, and concentration‐toxicity assays were conducted using H19‐7/IGF‐IR cells. Data were integrated with a maternal‐foetal physiologically based pharmacokinetic (PBPK) model to determine the maximum tolerated concentration. A clinical PBPK for dexamethasone in pregnant women was used to simulate a potentially optimal dosing regimen. Key Results The PK/PD model adequately characterised dexamethasone‐induced foetal lung maturation and indicated a minimal effective concentration of 1.63 ng·ml −1 . The offspring of PDE rats exhibited significant behavioural changes. mRNA sequencing analysis suggested that neurotoxicity was mediated via the Wnt pathway and renin‐angiotensin system, with BDNF and CMA1 identified as potential biomarkers of neurotoxicity. Cell‐based assays suggested a neurotoxic threshold concentration of 17 ng·ml −1 . For a therapeutic window of 1.63–17 ng·ml −1 , PBPK model simulations indicated that a reduced dose regimen of 2.5 or 3 mg every 8 h for six doses may represent an optimised therapeutic strategy. Conclusion and Implications This model‐informed precision dosing strategy provides a rational approach to optimising clinical dexamethasone dosing regimens.

British Journal of Pharmacology
Peking University (CN), Wuhan University (CN), Peking University Third Hospital (CN)
Good health and well-being
Neonatal Respiratory Health Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon